Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to two upcoming webcasts of Pfizer discussions at healthcare conferences:
- Mikael Dolsten, Chief Scientific Officer, President, Worldwide Research, Development and Medical, at Citi's 17th Annual BioPharma Conference on Wednesday, September 7, 2022 at 10:30 a.m. EDT; and
- David Denton, Chief Financial Officer, Executive Vice President, at the Wells Fargo 2022 Healthcare Conference on Thursday, September 8, 2022 at 9:10 a.m. EDT.
To view and listen to the webcasts, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcasts will be available at www.pfizer.com/investors beginning today.
The transcripts and webcast replays of the discussions will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussions and will be accessible for at least 90 days.
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
Disclosure Notice: The webcasts may include forward-looking statements about, among other things, expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, clinical trial results and other developing data, revenue contribution, growth, performance, timing of exclusivity and potential benefits, our anticipated operating and financial performance, reorganizations, business plans, strategy and prospects; strategic reviews; capital allocation objectives; plans for and prospects of our acquisitions, dispositions and other business development activities, and our ability to successfully capitalize on these opportunities; manufacturing and product supply; and our efforts to respond to COVID-19, including the Pfizer-BioNTech COVID-19 vaccine (Comirnaty) and our oral COVID-19 treatment (Paxlovid), that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. A description of these risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.
The forward-looking statements in each webcast speak only as of the original date of the webcast. Pfizer assumes no obligation to update forward-looking statements contained in the webcasts as the result of new information or future events or developments.